Evaluating only Sensei Biotherapeutics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
MILESTONE
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Sensei Biotherapeutics developed immuno-oncology combination therapies targeting immune checkpoints beyond PD-1. The company went public in 2021 raising $120M but clinical data failed to meet expectations. With cash running low and a failed 2022 fundraising attempt, the board shut down operations in August 2022.
Lesson
“Immuno-oncology combination strategies require differentiated mechanisms — a second checkpoint inhibitor is not differentiated enough.”